Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

ROCHE HOLDING LTD. (ROG)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE

Roche : names Pao as Swiss R&D head after Reed exits

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/08/2018 | 12:17pm CEST
Logo of Swiss drugmaker Roche is seen at its headquarters in Basel

ZURICH (Reuters) - Swiss drugmaker Roche said it will put a cancer specialist at the helm of its Swiss-based research efforts in April, after the scientist who led the unit for five years resigned for personal reasons.

ZURICH (Reuters) - Swiss drugmaker Roche said it will put a cancer specialist at the helm of its Swiss-based research efforts in April, after the scientist who led the unit for five years resigned for personal reasons.

The biggest maker of cancer drugs named William Pao to lead its 2,200-employee Pharma Research and Early Development (pRED) unit on Thursday.

Current postholder Reed, 59, arrived in Basel in 2013 to rebuild Roche's Swiss research after restructuring. He plans to return to the United States.

Pao now heads pRED's oncology discovery and translational area and will assume his new role on April 2, Roche said in a statement.

Roche has been touting prospective drugs from its long-underperforming Swiss-led research unit after years of leaning on its California-based Genentech arm for all of its blockbusters.

While pRED's drug hopefuls including autism and blood cancer agents have advanced under Reed to late-stage studies, planned filings for approval are still at least a year away.

"I am thankful to have had John Reed with Roche over the past five years, and for all his many valuable contributions," Chief Executive Severin Schwan said. He added Pao had been instrumental since coming to Roche in 2014 in building out cancer immunotherapy and molecular targeted therapies.

Before joining Roche, Reed, an expert in why cells die, did a 21-year stint at Sanford-Burnham Medical Research Institute in San Diego, California -- far from Roche's campus near the Rhine River at the Swiss, French and German borders.

Pao, who will be based in Basel, joined Roche in 2014 from the Vanderbilt University Medical Center in Nashville, Tennessee.

Under Reed, he has overseen pRED’s list of oncology hopefuls including CEA-TCB, a so-called bispecific antibody drug that brings a patient’s cancer-fighting T-cells closer to tumour cells to kill them.

Pao is also co-founder of MyCancerGenome, an online tool to enable a genetically informed approach to cancer medicine.

"William has been instrumental in the build-up of cancer immunotherapy and molecular targeted therapies," said Schwan.

(Reporting by Michael Shields and John Miller; editing by Brenna Hughes Neghaiwi and Elaine Hardcastle)

By John Miller

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ROCHE HOLDING LTD.
09/21AbbVie Gets Positive CHMP Opinion for Combination of Venclyxto With Rituximab..
DJ
09/13Roche Works to Fill Sales Gap as Biosimilars Emerge -Reuters
DJ
09/13Roche steps up efficiency drive to take sting out of biosimilars
RE
09/13ROCHE : FDA Approves Subcutaneous Formulation of Actemra for Use in Active Syste..
BU
09/13ROCHE : boss says Brexit and curbs on drug use pose threat to UK science
RE
09/10U.K. Health Regulator Rejects Roche's MS Drug
DJ
09/10ROCHE : faces UK pricing row over multiple sclerosis drug Ocrevus
RE
09/06FDA Extends Review Period for Roche Cancer Treatment License
DJ
09/06GENENTECH : to Present New Data from Its Extensive Lung Cancer Program at the 20..
BU
09/04With drugs pipeline in focus, Bayer considers job cuts
RE
More news
News from SeekingAlpha
09/22STOCKS TO WATCH : Calling Up Animal Spirits 
09/21Key events next week - healthcare 
09/21New opinions from EMA advisor CHMP 
09/20Arvinas Holding Prepares Terms For $100 Million IPO 
09/18Roche launches two NAVIFY clinical decision support apps 
Financials (CHF)
Sales 2018 56 475 M
EBIT 2018 19 233 M
Net income 2018 12 946 M
Debt 2018 4 708 M
Yield 2018 3,74%
P/E ratio 2018 15,54
P/E ratio 2019 15,24
EV / Sales 2018 3,67x
EV / Sales 2019 3,52x
Capitalization 203 B
Chart ROCHE HOLDING LTD.
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING LTD.
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 259  CHF
Spread / Average Target 10%
EPS Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.-4.60%211 501
JOHNSON & JOHNSON1.62%383 312
PFIZER21.65%258 285
NOVARTIS-0.63%216 108
MERCK AND COMPANY25.79%189 092
AMGEN17.94%132 756